By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Entelos, Inc. 

110 Marsh Drive

Foster City  California  94404  U.S.A.
Phone: 650-572-5400 Fax: 650-572-5401


Entelos, Inc., headquartered in Foster City, California, is the commercial leader in predictive biosimulation. The company builds in silico disease models—called PhysioLab® systems—and creates “virtual patients” to significantly reduce the time, cost, and risk required to discover and develop new drugs. Entelos collaborates with global pharmaceutical and biotechnology companies in the areas of metabolic and inflammatory diseases such as asthma, obesity, diabetes, and rheumatoid arthritis, and its biosimulation systems have been used to validate novel drug targets, select and develop compounds, optimize clinical trials and combination therapies, reprofile drugs, evaluate in-licensing candidates, and better position existing products in competitive markets. The company employs life scientists with expertise spanning molecular biology to clinical medicine in fields related to metabolism, inflammation, and immunology and engineers with backgrounds in whole-system control dynamics, including chemical, electrical, mechanical, and aeronautical engineering.

Key Management:
James Karis, President and Chief Executive Officer
Alex L. Bangs, Co-Founder and Chief Technology Officer
Alan Blazei, Chief Financial Officer
Mikhail Gishisky, Chief Scientific Officer
June Ameen, Vice President Business Development & Alliances
Scott Clarke, Vice President and General Manager
Thomas Paterson, Co-Founder and Senior Vice President
John T. Rigsbee, J.D., Ph.D., General Counsel

Last Updated: 10-02-2006

Key Statistics

Ownership: Private

Web Site: Entelos, Inc.
Employees: 90+


Company News
Entelos, Inc. Expands Senior Management Team 1/31/2012 6:58:10 AM
Clearlake and Imperium Release: Entelos, Inc. Announces Recapitalization and Significant Capital Infusion to Drive Future Growth 1/11/2012 6:34:42 AM
Simulations Plus (SLP) Bid for Assets of Entelos, Inc. Not Selected 9/28/2011 9:59:34 AM
Simulations Plus (SLP) Submits Bid in Chapter 11 Bankruptcy Proceedings for Assets of Entelos, Inc. 9/20/2011 10:16:35 AM
Entelos, Inc. Granted Patent for Predictive Toxicology for Biological Systems 1/10/2011 11:45:12 AM
Entelos, Inc. Agrees to Expanded License Terms with Pfizer Inc. (PFE) 6/24/2010 6:59:59 AM
Entelos, Inc. Announces Publication of Its Type 1 Diabetes PhysioLab(R) Platform, a Computer Model to Aid in the Development of Novel Therapeutic Approaches 6/2/2010 10:50:46 AM
Entelos, Inc. and RegeneMed Introduce iToxFX to Help Predict the Safety of New Drugs 3/8/2010 9:24:40 AM
Entelos, Inc. Granted Patent for Innovative Diagnostic Capability in Obesity, Diabetes 2/3/2010 9:56:41 AM
GeneGo, Inc. Announces Systems Tox Relationship With Entelos, Inc. 3/17/2009 11:34:11 AM